TY - JOUR
T1 - Chronic migraine
T2 - Classification and comparisons
AU - Katsarava, Z.
AU - Manack, A.
AU - Yoon, M. S.
AU - Obermann, M.
AU - Becker, H.
AU - Dommes, P.
AU - Turkel, C.
AU - Lipton, R. B.
AU - Diener, H. C.
N1 - Funding Information:
ZK has received research grants and honoraria from Allergan and Bayer, and is an advisory board member for Allergan. Headache research at the Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF), and the European Union. AM and CCT are employees of Allergan, Inc. MSY has nothing to disclose. MO has nothing to disclose. PD has nothing to disclose. RBL has received honoraria and research funding from Allergan, in addition to serving as a consultant to and on the advisory board of Allergan. HCD has received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Addex Pharma, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Eli Lilly, La Roche, 3M Medica, Minster, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper & Brümmer, Sanofi-Aventis and Weber & Weber; and has received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag and Pfizer.
Funding Information:
This research project was funded by the German Federal Ministry for Education and Research. Additional analyses were supported by Allergan, Inc., Irvine, CA, USA. The authors would like to thank Allergan, Inc., for funding and IntraMed Educational Group, New York, NY, for providing editorial support in the preparation and styling of this manuscript.
PY - 2011/5
Y1 - 2011/5
N2 - Objective: The objective of our study was to field test different chronic migraine (CM) criteria and compare CM epidemiological profiles, which include demographic, personal, and lifestyle characteristics, with high-frequency episodic migraine (HFEM) and low-frequency episodic migraine (LFEM). Methods: Questionnaires were mailed to a random sample of 18,000 18-65-year-olds in demographically diverse regions of Germany. The epidemiological data for the three classifications of CM, LFEM and HFEM were assessed using descriptive statistics, Pearson Chi-square, and analysis of variance tests. Results: Among 9350 respondents, CM-I was the most restrictive (N = 37, 0.4%), followed by CM-II (N = 45, 0.5%) and CM-III (N = 185, 2.0%). CM groups did not differ in distribution by age, gender, body mass index, education or smoking and alcohol consumption. Compared to those with LFEM and HFEM, those with CM (CM-III) had significantly different epidemiological profiles. Conclusions: CM prevalence varies by case definition. The epidemiological profiles of the three CM groups are similar but differ significantly from those of HFEM and LFEM. Optimal definitions for clinical practice and epidemiological research require additional field testing.
AB - Objective: The objective of our study was to field test different chronic migraine (CM) criteria and compare CM epidemiological profiles, which include demographic, personal, and lifestyle characteristics, with high-frequency episodic migraine (HFEM) and low-frequency episodic migraine (LFEM). Methods: Questionnaires were mailed to a random sample of 18,000 18-65-year-olds in demographically diverse regions of Germany. The epidemiological data for the three classifications of CM, LFEM and HFEM were assessed using descriptive statistics, Pearson Chi-square, and analysis of variance tests. Results: Among 9350 respondents, CM-I was the most restrictive (N = 37, 0.4%), followed by CM-II (N = 45, 0.5%) and CM-III (N = 185, 2.0%). CM groups did not differ in distribution by age, gender, body mass index, education or smoking and alcohol consumption. Compared to those with LFEM and HFEM, those with CM (CM-III) had significantly different epidemiological profiles. Conclusions: CM prevalence varies by case definition. The epidemiological profiles of the three CM groups are similar but differ significantly from those of HFEM and LFEM. Optimal definitions for clinical practice and epidemiological research require additional field testing.
KW - Chronic migraine
KW - classification
KW - definition
KW - epidemiology
UR - http://www.scopus.com/inward/record.url?scp=79953196522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953196522&partnerID=8YFLogxK
U2 - 10.1177/0333102410383590
DO - 10.1177/0333102410383590
M3 - Article
C2 - 21220376
AN - SCOPUS:79953196522
SN - 0333-1024
VL - 31
SP - 520
EP - 529
JO - Cephalalgia
JF - Cephalalgia
IS - 5
ER -